非小细胞肺癌患者血清Ras相关区域家族1A基因启动子异常甲基化检测及其临床意义  

Analysis of RASSFIA promoter hypermethylation in serum DNA of non-small cell lung cancer patients

作　　者：于正洪[1] 王玉才[1] 陈龙邦[1] 宋勇[2] 刘畅[1] 夏欣一[3] 林勍[1] 马驰原[4] 

机构地区：[1]南京军区南京总医院肿瘤内科,210002 [2]南京军区南京总医院呼吸内科,210002 [3]南京军区南京总医院中心实验科,210002 [4]南京军区南京总医院博士后站,210002

出　　处：《中华肿瘤杂志》2008年第4期284-287,共4页Chinese Journal of Oncology

基　　金：南京军区南京总医院科研基金资助项目（2005018）;江苏省六大人才高峰重点基金资助项目（2005A2）

摘　　要：目的研究非细胞肺癌（NSCLC）患者血清Ras相关区域家族1A（RASSF1A）基因启动子区域的甲基化状态及其临床意义。方法采用甲基化特异性聚合酶链反应（MSP）技术，检测75例NSCLC患者血清RASSF1A基因启动子区域的甲基化状态，并分析其与临床病理参数之间的相关性。结果75例NSCLC患者血清RASSF1A基因启动子区域异常甲基化检出率为30．7％（23／75），而35例肺部良性疾病患者和15例健康志愿者中检出率均为0，差异有统计学意义（P〈0．001）。RASSF1A启动子异常甲基化与NSCLC患者的年龄、性别、病理类型无显著相关性，但在晚期及肿瘤分化程度较低的患者中检出率较高（P〈0．05）。结论RASSF1A启动子异常甲基化在NSCLC的发生、发展中起重要作用，有望成为NSCLC辅助诊断和预后判断的分子标记。ObjecUve To detect the hypermethylation status of RASSF1A promoter in serum DNA of non-small cell lung cancer （NSCLC） patient and evaluate its correlation with clinicopathological parameters. Methods Serum DNA was extracted from the peripheral blood of 75 NSCLC patients and another 35 patients with benign pulmonary disease and 15 healthy donors. The methylation status of RASSF1A promoter was determined using mthylation-specific PCR （MSP）, and the correlation of methylation profiles with clinicopathological parameters was statistically analyzed. Results Aberrant methylation of RASSF1A was detected in 23 of 75 （30.7%） cancer patients, but in none of patients with benign pulmonary disease or in healthy donors （ P 〈 O. 001 ）. RASSF1A hypermethylation status was found to be correlated with late stage and poor differentiation （ P 〈 O. 05 ）, but not with gender, age or histopathology in NSCLC patients. Conclusion Hypermethylated RASSF1A promoter is frequently found in the serum DNA of non-small cell lung cancer patient, and RASSF1A may become a promising novel biomarker for diagnosis and prognosis prediction in lung cancer.

关 键 词：非小细胞肺癌 RASSFlA基因 抑癌基因 DNA甲基化 

分 类 号：R686[医药卫生—骨科学]